ANCA glomerulonephritis after the Moderna COVID-19 vaccination

Sekar, Arjun; Campbell, Ruth; Tabbara, Jad; Rastogi, Prerna

doi:10.1016/j.kint.2021.05.017

Cited by 105 publications

(80 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior cases have been mainly reported among elderly individuals without known renal diseases. Six cases have been associated with a mRNA vaccine, while a viral vector vaccine has been associated with two cases (8)(9)(10)(11)(12)(13)(14). AAV was diagnosed after either the first dose (37.5%) or second dose (62.5%) of COVID-19 vaccination.…”

Section: Discussionmentioning

confidence: 99%

Case Report: Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis With Acute Renal Failure and Pulmonary Hemorrhage May Occur After COVID-19 Vaccination

Chen

et al. 2021

Front. Med.

View full text Add to dashboard Cite

The rare and severe adverse effects associated with coronavirus disease of 2019 (COVID-19) vaccination have been under-appreciated, resulting in many instances of inappropriate management. We describe the case of an elderly woman who developed anti-neutrophil cytoplasmic antibody-associated vasculitis with pulmonary renal syndrome approximately 3 weeks after the first dose of COVID-19 mRNA vaccination (Moderna). Her nasopharyngeal polymerase chain reaction test for the COVID-19 RNA virus was negative. Gross hematuria, heavy proteinuria, acute renal failure (serum creatinine up to 6.5 mg/dL), and hemoptysis coupled with a marked increase in serum anti-myeloperoxidase-O antibody were observed. Renal biopsy showed severe vasculitis with pauci-immune crescent glomerulonephritis. The pulmonary hemorrhage was resolved and renal function improved following combined plasma exchange and the administration of systemic steroids and anti-CD20 therapy. The early examination of urinalysis and renal function may be crucial for identifying glomerulonephritis and acute renal failure in susceptible patients after COVID-19 vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

Case Report: Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis With Acute Renal Failure and Pulmonary Hemorrhage May Occur After COVID-19 Vaccination

Chen

et al. 2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Generally, renal manifestations in AAV are estimated at 80% among all cases mainly manifesting as ANCA-associated glomerulonephritis (ANCA GN), and the overall prevalence does not seem to differ substantially between MPO-ANCA and PR3-ANCA AAV (6). Interestingly, five cases of renal AAV presenting with pauci-immune crescentic ANCA GN after COVID-19 mRNA vaccination have already been reported (7)(8)(9)(10). We here expand our current knowledge of this rare but important association and report a case of AAV presenting with massive rhabdomyolysis and pauci-immune crescentic GN after Pfizer-BioNTech COVID-19 mRNA vaccination.…”

Section: Introductionmentioning

confidence: 99%

Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination

Hakroush

Tampe

2021

Front. Immunol.

View full text Add to dashboard Cite

As the coronavirus disease 2019 (COVID-19) pandemic is ongoing and new variants of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are emerging, there is an urgent need for COVID-19 vaccines to control disease outbreaks by herd immunity. Surveillance of rare safety issues related to these vaccines is progressing, since more granular data emerge with regard to adverse events of COVID-19 vaccines during post-marketing surveillance. Interestingly, four cases of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) presenting with pauci-immune crescentic glomerulonephritis (GN) after COVID-19 mRNA vaccination have already been reported. We here expand our current knowledge of this rare but important association and report a case of AAV presenting with massive rhabdomyolysis and pauci-immune crescentic GN after Pfizer-BioNTech COVID-19 mRNA vaccination. As huge vaccination programs are ongoing worldwide, post-marketing surveillance systems must continue to assess vaccine safety important for the detection of any events associated with COVID-19 vaccination. This is especially relevant in complex diseases where diagnosis is often challenging, as in our patient with AAV presenting with massive rhabdomyolysis and pauci-immune crescentic GN.

show abstract

“…Recently, a few cases have been reported of patients developing either anti-GBM nephritis or ANCA-mediated nephritis following vaccinations with either the Pfizer-BioNTech and Moderna SARS-CoV-2 mRNA vaccines. 1 , 2 We describe a rare case of concurrent anti-GBM and ANCA-mediated glomerulonephritis following COVID-19 vaccination with the second dose of the Moderna vaccine.…”

mentioning

confidence: 99%

Concurrent Antiglomerular Basement Membrane Nephritis and Antineutrophil Cytoplasmic Autoantibody–Mediated Glomerulonephritis After Second Dose of SARS-CoV-2 mRNA Vaccination

ANCA glomerulonephritis after the Moderna COVID-19 vaccination

Cited by 105 publications

References 5 publications

Case Report: Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis With Acute Renal Failure and Pulmonary Hemorrhage May Occur After COVID-19 Vaccination

Case Report: Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis With Acute Renal Failure and Pulmonary Hemorrhage May Occur After COVID-19 Vaccination

Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination

Concurrent Antiglomerular Basement Membrane Nephritis and Antineutrophil Cytoplasmic Autoantibody–Mediated Glomerulonephritis After Second Dose of SARS-CoV-2 mRNA Vaccination

Contact Info

Product

Resources

About